As of 2025-06-17, the EV/EBITDA ratio of Blueprint Medicines Corp (BPMC) is -54.23. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BPMC's latest enterprise value is 8,547.89 mil USD. BPMC's TTM EBITDA according to its financial statements is -157.63 mil USD. Dividing these 2 quantities gives us the above BPMC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.0x - 10.5x | 9.3x |
| Forward P/E multiples | 9.3x - 11.3x | 11.1x |
| Fair Price | (26.81) - (29.84) | (29.01) |
| Upside | -120.9% - -123.3% | -122.6% |
| Date | EV/EBITDA |
| 2025-06-16 | -54.23 |
| 2025-06-13 | -54.11 |
| 2025-06-12 | -54.21 |
| 2025-06-11 | -54.11 |
| 2025-06-10 | -54.11 |
| 2025-06-09 | -54.11 |
| 2025-06-06 | -54.06 |
| 2025-06-05 | -54.09 |
| 2025-06-04 | -54.17 |
| 2025-06-03 | -53.96 |
| 2025-06-02 | -54.04 |
| 2025-05-30 | -43.21 |
| 2025-05-29 | -43.91 |
| 2025-05-28 | -40.73 |
| 2025-05-27 | -42.68 |
| 2025-05-23 | -43.27 |
| 2025-05-22 | -42.79 |
| 2025-05-21 | -43.27 |
| 2025-05-20 | -43.88 |
| 2025-05-19 | -43.15 |
| 2025-05-16 | -43.35 |
| 2025-05-15 | -42.45 |
| 2025-05-14 | -41.63 |
| 2025-05-13 | -42.41 |
| 2025-05-12 | -42.78 |
| 2025-05-09 | -41.50 |
| 2025-05-08 | -42.15 |
| 2025-05-07 | -42.57 |
| 2025-05-06 | -42.31 |
| 2025-05-05 | -43.41 |
| 2025-05-02 | -44.56 |
| 2025-05-01 | -42.35 |
| 2025-04-30 | -38.35 |
| 2025-04-29 | -37.93 |
| 2025-04-28 | -37.95 |
| 2025-04-25 | -37.60 |
| 2025-04-24 | -36.96 |
| 2025-04-23 | -36.84 |
| 2025-04-22 | -35.86 |
| 2025-04-21 | -36.17 |
| 2025-04-17 | -36.38 |
| 2025-04-16 | -35.32 |
| 2025-04-15 | -35.05 |
| 2025-04-14 | -35.50 |
| 2025-04-11 | -34.80 |
| 2025-04-10 | -34.57 |
| 2025-04-09 | -35.30 |
| 2025-04-08 | -34.14 |
| 2025-04-07 | -34.54 |
| 2025-04-04 | -35.15 |